Helen Hobbs
✓ Source-basedfallingAmerican molecular geneticist
Helen Haskell Hobbs is an American medical researcher who is professor at the University of Texas Southwestern Medical Center, and a Howard Hughes Medical Institute Investigator, who won a 2016 Breakthrough Prize in Life Sciences and the 2018 Harrington Prize for Innovation in Medicine.
Also inDeutsch
Awards 10
Connected to Helen 6
Simon FlexnerAlso won George M. Kober Lectureship
Nicole Marthe Le DouarinAlso won Pearl Meister Greengard Prize
Jeffrey M. FriedmanAlso won Robert J. and Claire Pasarow Foundation Award for Distinguished Contributions to Cardiovascular Research
Andrzej StelmachowskiAlso won honorary doctor of the University of Ferrara
Pascale CossartAlso won Heinrich Wieland Prize
Michel HaïssaguerreAlso won Scientific Grand Prize of the Lefoulon-Delalande FondationAbout this person
Helen Haskell Hobbs is an American medical researcher who is professor at the University of Texas Southwestern Medical Center, and a Howard Hughes Medical Institute Investigator, who won a 2016 Breakthrough Prize in Life Sciences and the 2018 Harrington Prize for Innovation in Medicine. Hobbs specializes in the dysregulation of lipid metabolism and how it affects human diseases. She and Jonathan C. Cohen found that people with hypomorphic PCSK9 mutations had lower LDL-cholesterol levels and were almost immune to heart disease. This finding led to the development of a new class of cholesterol-lowering drugs that mimic the effects of the PCSK9 mutations. She and Cohen also identified the first genetic risk factor for fatty liver disease, a burgeoning health problem that can lead to cirrhosis and liver cancer. Their laboratory has shown that mutation in PNPLA3 causes accumulation of PNPLA3 on lipid droplets, which compromises the mobilization of triglycerides from liver cells. She sits on the Board of Directors at Pfizer.
United StatesFame.am measures public visibility signals. It does not measure human value, talent, morality, or credibility.